Price
$23.32+16.72%Social Signal Score
Analyst Ratings
11 analystsRevenue
$106.31MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ying Du
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,784
- Beta
- 0.83
- Country
- CN
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.36
Financials
Revenue
$106.31M+82023.9%Net Income
$-50.83MEBITDA
$-46.09MFree Cash Flow
$-64.87MEPS (diluted)
$-0.50Shares Outstanding (diluted)
111.70M+11492.0%Operating Expenses
$134.64MCash & Debt
$617.52MReturn of Capital
$0.00Revenue by Segment (annual)
$334.53MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $460.16M | $-175.54M | $-1.60 |
| 2024 | $398.99M | $-257.10M | $-2.60 |
| 2023 | $266.72M | $-334.62M | $-34.60 |
| 2022 | $215.04M | $-443.29M | $-46.30 |
| 2021 | $144.31M | $-704.47M | $-75.80 |
| 2020 | $48.96M | $-268.90M | $-34.60 |
| 2019 | $12.98M | $-195.07M | $-30.30 |
| 2018 | $129.5K | $-139.07M | $-26.40 |
| 2017 | $0.00 | $-50.38M | $-23.20 |
| 2016 | $0.00 | $-37.51M | $-39.70 |
| 2015 | $0.00 | $-18.02M | $-20.70 |
Valuation
ZLABhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newscnbc.com·40d ago·Neutral
Z.ai shares surge 8% after releasing new AI model running only on Chinese chips Z.ai's shares rose after the company launched a new AI model that it claimed runs only on Chinese chips. It's the latest indication of China's efforts to ramp up homegrown computing capability.
View source ↗ - Newsseekingalpha.com·48d ago·Negative
Zai Lab: Revenue Growth And Zoci's Upside Optionality ZLAB has grown from a Greater China licensing platform into a dual-engine biopharma. They have a growing proprietary global pipeline with KarXT and TIVDAK. And management expects product sales to stabilize during 2H2026. Zoci's SCLC and NEC activity looks promising, while their other partnered combo therapies could expand their indications across other treatments.
View source ↗ - Newsbusinesswire.com·50d ago·Positive
… Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint (p=0.0011) In the combined immune-mediated necrotizing myopathy (IMN…
View source ↗ - Newsmarketbeat.com·59d ago·Neutral
Zai Lab Q2 Earnings Call Highlights Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.56 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.46 vs $-0.68beat
- Thu, May 7$-0.46 vs $-0.53beat
- Thu, Feb 26$-0.46 vs $-0.44miss
- Thu, Nov 6$-0.33 vs $-0.28miss
- Thu, Aug 7$-0.37 vs $-0.37beat
- Thu, May 8$-0.45 vs $-0.50beat
Estimates and results for ZLAB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZLAB officers and directors.
- Bought
- $33k
- Sold
- $6.0m
1 trade
24 trades
- Chen Yajingsold
- Lis Williamsold
- Chen Yajingsold
- Gaynor Richardbought
- Du Yingsold
- Edmondson Frazor Titus Iiisold
- Du Yingsold
- Chen Yajingsold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ZLAB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.